Slattery Patrick, Frölich Stefanie, Schreiber Yannik, Nüsing Rolf M
Institute of Clinical Pharmacology, Goethe-University, Frankfurt, Germany; and.
Fraunhofer IME, Goethe-University, Frankfurt, Germany.
Am J Physiol Renal Physiol. 2016 May 15;310(10):F1113-22. doi: 10.1152/ajprenal.00430.2015. Epub 2016 Mar 16.
Deletion of cyclooxygenase (COX)-2 causes impairment of kidney development, including hypothrophic glomeruli and cortical thinning. A critical role for COX-2 is seen 4-8 days postnatally. The present study was aimed at answering whether different COX-2 gene dosage and partial pharmacological COX-2 inhibition impairs kidney development. We studied kidney development in COX-2(+/+), COX-2(+/-), and COX-2(-/-) mice as well as in C57Bl6 mice treated postnatally with low (5 mg·kg(-1)·day(-1)) and high (10 mg·kg(-1)·day(-1)) doses of the selective COX-2 inhibitor SC-236. COX-2(+/-) mice exhibit impaired kidney development leading to reduced glomerular size but, in contrast to COX-2(-/-) mice, only marginal cortical thinning. Moreover, in COX-2(+/-) and COX-2(-/-) kidneys, juxtamedullary glomeruli, which develop in the very early stages of nephrogenesis, also showed a size reduction. In COX-2(+/-) kidneys at the age of 8 days, we observed significantly less expression of COX-2 mRNA and protein and less PGE2 and PGI2 synthetic activity compared with COX-2(+/+) kidneys. The renal defects in COX-2(-/-) and COX-2(+/-) kidneys could be mimicked by high and low doses of SC-236, respectively. In aged COX-2(+/-) kidneys, glomerulosclerosis was observed; however, in contrast to COX-2(-/-) kidneys, periglomerular fibrosis was absent. COX-2(+/-) mice showed signs of kidney insufficiency, demonstrated by enhanced serum creatinine levels, quite similar to COX-2(-/-) mice, but, in contrast, serum urea remained at the control level. In summary, function of both COX-2 gene alleles is absolutely necessary to ensure physiological development of the mouse kidney. Loss of one copy of the COX-2 gene or partial COX-2 inhibition is associated with distinct renal damage and reduced kidney function.
环氧化酶(COX)-2的缺失会导致肾脏发育受损,包括肾小球萎缩和皮质变薄。COX-2在出生后4-8天发挥关键作用。本研究旨在回答不同的COX-2基因剂量和部分药理学COX-2抑制是否会损害肾脏发育。我们研究了COX-2(+/+)、COX-2(+/-)和COX-2(-/-)小鼠以及出生后用低剂量(5 mg·kg(-1)·天(-1))和高剂量(10 mg·kg(-1)·天(-1))选择性COX-2抑制剂SC-236处理的C57Bl6小鼠的肾脏发育情况。COX-2(+/-)小鼠表现出肾脏发育受损,导致肾小球大小减小,但与COX-2(-/-)小鼠不同的是,仅出现轻微的皮质变薄。此外,在COX-2(+/-)和COX-2(-/-)小鼠的肾脏中,在肾发生早期发育的近髓肾小球也出现了大小减小。在8天大的COX-2(+/-)小鼠肾脏中,与COX-2(+/+)小鼠肾脏相比,我们观察到COX-2 mRNA和蛋白的表达显著减少,PGE2和PGI2的合成活性也降低。COX-2(-/-)和COX-2(+/-)小鼠肾脏中的肾脏缺陷分别可被高剂量和低剂量的SC-236模拟。在老年COX-2(+/-)小鼠肾脏中,观察到肾小球硬化;然而,与COX-2(-/-)小鼠肾脏不同的是,没有肾小球周围纤维化。COX-2(+/-)小鼠表现出肾功能不全的迹象,血清肌酐水平升高证明了这一点,这与COX-2(-/-)小鼠非常相似,但相比之下,血清尿素仍保持在对照水平。总之,COX-2基因的两个等位基因的功能对于确保小鼠肾脏的生理发育绝对必要。COX-2基因一个拷贝的缺失或部分COX-2抑制与明显的肾脏损伤和肾功能降低有关。